- Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumabNathan Vastesaeger
Department of Medical Affairs, MSD Danmark ApS, Ballerup, Denmark
Rheumatology (Oxford) 55:1466-76. 2016..To create a tool to predict probability of remission and low disease activity (LDA) in patients with RA being considered for anti-TNF treatment in clinical practice...
- ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapyNathan Vastesaeger
Merck Sharp and Dohme, Brussels, Belgium Electronic address
Reumatol Clin 10:204-9. 2014..To investigate which of the 2 ankylosing spondylitis (AS) disease activity instruments identifies better those patients with characteristics that have been associated with positive response to anti-TNF therapy...
- Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND studyAsta Baranauskaite
Kaunas Medical University Hospital, Kaunas, Lithuania
Ann Rheum Dis 71:541-8. 2012..To compare the efficacy and safety of treatment with infliximab plus methotrexate with methotrexate alone in methotrexate-naive patients with active psoriatic arthritis (PsA)...
- Predicting the outcome of ankylosing spondylitis therapyNathan Vastesaeger
Schering Plough Corporation, Kenilworth, New Jersey, USA
Ann Rheum Dis 70:973-81. 2011....